1x 베팅 주소 Pharmaceutical Co., Ltd.

1x 베팅 주소 Pharmaceutical Co., Ltd. and Akebia Therapeutics, Inc. have entered into a new, additional agreement that expands their existing relationship for development and marketing of vadadustat, under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia).

The two companies previously concluded a co-development and co-market1x 베팅 주소g agreement 1x 베팅 주소 December 2016 that covers the U.S.

The new, additional agreement covers European markets, where 1x 베팅 주소 and Akebia will jointly develop vadadustat and 1x 베팅 주소 will market it, and other markets including China, Canada, Australia, etc.* (but excluding Latin America), where 1x 베팅 주소 will develop and market it. (Marketing vadadustat is contingent on receiving regulatory approvals.)

• 1x 베팅 주소 2015 Akebia entered 1x 베팅 주소to a licens1x 베팅 주소g agreement with Mitsubishi Tanabe Pharmaceutical cover1x 베팅 주소g Japan and specific other Asian countries (Taiwan, Korea, S1x 베팅 주소gapore, Malaysia, 1x 베팅 주소donesia, etc.)